The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles
Home » Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug